SCH-50911
SCH-50911，分子式C8H15NO3，是一种γ-氨基丁酸β受体（GABAB）选择性拮抗剂[1]，用于治疗酒精戒断症候群中的震颤性谵妄而开发[2]。
| SCH-50911 | |
|---|---|
| |
| IUPAC名 2-[(2S)-5,5-Dimethylmorpholin-2-yl]acetic acid | |
| 识别 | |
| CAS号 | 160415-07-6 
|
| PubChem | 5311429 |
| ChemSpider | 4470917 |
| SMILES |
|
| InChI |
|
| InChIKey | SEYCKMQSPUVYEF-LURJTMIEBV |
| MeSH | SCH-50911 |
| IUPHAR配体 | 1075 |
| 性质 | |
| 化学式 | C8H15NO3 |
| 摩尔质量 | 173.21 g·mol⁻¹ |
| 熔点 | 154.5-157 °C（428-430 K）（盐酸盐） |
| 若非注明，所有数据均出自标准状态（25 ℃，100 kPa）下。 | |
参考文献
- ^ Blythin DJ, Kuo SC, Shue HJ, McPhail AT, Chapman RW, Kreutner W, et al. Substituted morpholine-2S-acetic acid derivatives: Sch 50911 and related compounds as novel GABAB antagonists.. Bioorganic & Medicinal Chemistry Letters. July 1996, 6 (13): 1529–34. doi:10.1016/S0960-894X(96)00267-3.
- ^ Quang LS, Colombo G, Lobina C, Maccioni P, Orru A, Gessa GL, et al. Evaluation for the withdrawal syndrome from gamma-hydroxybutyric acid (GHB), gamma-butyrolactone (GBL), and 1,4-butanediol (1,4-BD) in different rat lines. Annals of the New York Academy of Sciences. August 2006, 1074: 545–58. PMID 17105952. doi:10.1196/annals.1369.055.